News

The University and biOasis continue to develop biOasis’ extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier

A therapeutically aligned infectious diseases team will support all ID studies at PSI, focused to provide optimized approaches to patient enrollment. The team will include staff from various

The acquisition reflects the organization’s recent growth, allowing DPT to expand its footprint in Lakewood by adding two buildings totaling 90,000 square feet of space. The real estate

The results of this Phase 2 study, investigating the efficacy and safety of this topical ACT1 formulation when combined with standard care in treatment of chronic venous leg

Ascendia has advanced the program to pre-IND development stage, and has filed US and worldwide PCT patent applications on the product. "There is a significant unmet medical need

The new patent contains a composition of matter claim covering the use of the company’s ion exchange formulation of benzonatate. Claims for using benzonatate polacrilex to reduce or

Initially, the deal will focus on the development of the WT1 vaccine to treat leukemia, mesothelioma, and multiple myeloma, followed by additional solid tumor indications. In order to

Ipafricept is a first-in-class fusion protein that inhibits a key signaling pathway in cancer, the Wnt pathway. The FDA removed the partial clinical hold, after the company submitted

The MAA is based on the positive results from the data collected in Japan as part of the Phase III VIBRANT trial. The trial, which met its primary